Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial

DOI: 10.1186/s13063-018-3053-1

Keywords: Tuberculosis, Multidrug-resistant tuberculosis, Multicenter randomized trial, Non-inferiority, Shorter regimen, Delamanid, Linezolid

Full-Text   Cite this paper   Add to My Lib

Abstract:

The online version of this article (10.1186/s13063-018-3053-1) contains supplementary material, which is available to authorized users

Full-Text